Trends in clomiphene citrate and gonadotropins use in women with infertility between 2010 and 2017: A population‐based study in France

Abstract

AbstractPurposeTo describe temporal trends and assess factors associated with changes in the prescription of clomiphene citrate and gonadotropins between 2010 and 2017 in women with infertility aged 18–50 from metropolitan France.Methods6321 prevalent women from a representative sample of the national medico‐administrative database were identified. We performed a Cochran‐Armitage trend test and calculated the rate ratios. A Poisson regression was used to derive the incidence rate ratios, for each treatment class.ResultsThe prevalence rate and incidence rate of clomiphene citrate use significantly decreased by 20% (RR 0.80: 95% CI 0.71–0.90) and 23% (RR 0.77: 95% CI 0.66–0.89), respectively. Its initiation was higher in all age groups compared to the reference (18–24 years), with a downward gradient. It was also higher when the density of gynaecologists was higher and in disadvantaged areas. The prevalence rate and incidence rate of gonadotropin use increased by 11% (RR 1.11: 95% CI 1.01–1.22) and 33% (RR 1.33: 95% CI 1.14–1.55) respectively. Gonadotropin initiation was highest in the 31–35 age group, but it was also higher in the 25–30 and 36–40 age groups at a similar level (reference 18–24 years). Its initiation was higher when the density of gynaecologists was higher, but not associated with social deprivation.ConclusionOur results showed an increase in gonadotropin use for infertility treatment in France during the 2010–2017 period and a decrease in clomiphene citrate use. Further work should be undertaken to analyse the use of these drugs in relation to women's care pathways.